Iconovo Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Iconovo şirketinin kazançları yıllık ortalama -27.6% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 22.9% oranında artan oldu. Gelirler yıllık ortalama 11% oranında artan oldu.

Anahtar bilgiler

-27.6%

Kazanç büyüme oranı

-18.3%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	6.2%
Gelir büyüme oranı	11.0%
Özkaynak getirisi	-36.0%
Net Marj	-160.9%
Sonraki Kazanç Güncellemesi	27 Feb 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Iconovo AB (publ)'s (STO:ICO) Intrinsic Value Is Potentially 37% Above Its Share Price

Jun 13

Companies Like Iconovo (STO:ICO) Can Afford To Invest In Growth

Apr 13

When Will Iconovo AB (publ) (STO:ICO) Turn A Profit?

Mar 18

Have Iconovo AB (publ) (STO:ICO) Insiders Been Selling Their Stock?

Feb 20

A Look At Iconovo's (STO:ICO) Share Price Returns

Feb 07

Gelir ve Gider Dağılımı

Iconovo nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:ICO Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	25	-40	50
30 Jun 24	27	-39	52
31 Mar 24	28	-42	58
31 Dec 23	28	-46	61
30 Sep 23	31	-53	67
30 Jun 23	36	-53	66
31 Mar 23	43	-52	62
31 Dec 22	47	-48	59
30 Sep 22	49	-40	52
30 Jun 22	54	-34	49
31 Mar 22	49	-28	45
31 Dec 21	43	-26	42
30 Sep 21	41	-22	41
30 Jun 21	31	-20	39
31 Mar 21	24	-20	37
31 Dec 20	23	-17	34
30 Sep 20	15	-20	31
30 Jun 20	13	-20	29
31 Mar 20	13	-16	27
31 Dec 19	17	-11	25
30 Sep 19	22	-2	23
30 Jun 19	19	-3	20
31 Mar 19	20	0	18
31 Dec 18	15	-4	16
30 Sep 18	21	-1	17
30 Jun 18	20	-2	16
31 Mar 18	23	-1	18
31 Dec 17	22	1	16
31 Dec 16	18	3	14

Kaliteli Kazançlar: ICO şu anda kârlı değil.

Büyüyen Kar Marjı: ICO şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ICO kârlı değildir ve zararlar son 5 yılda yılda 27.6% oranında artmıştır.

Büyüme Hızlandırma: ICO 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: ICO kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 31% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: ICO hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -35.99% ) sahiptir.

Iconovo Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Recent updates

Consensus revenue estimates decrease by 46%, EPS upgraded

Price target decreased by 22% to kr16.75

Iconovo AB (publ) has completed a Composite Units Offering in the amount of SEK 28.653075 million.

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2024 earnings released: kr0.70 loss per share (vs kr0.97 loss in 3Q 2023)

Iconovo Initiates Development of the GLP-1 Antibody Semaglutide in the Inhaler Iocone Nasal

New minor risk - Share price stability

Price target increased by 12% to kr23.50

New major risk - Market cap size

Should You Investigate Iconovo AB (publ) (STO:ICO) At kr6.68?

Now 21% undervalued after recent price drop

Consensus revenue estimates increase by 17%

Iconovo AB (publ) Develops Intranasally Inhaled Semaglutide in ICOone Nasal for More User-Friendly Treatment of Overweight and Obesity

Vice President of Operations recently bought kr57k worth of stock

Second quarter 2024 earnings released: kr0.60 loss per share (vs kr1.32 loss in 2Q 2023)

Now 21% overvalued after recent price rise

Iconovo AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vice President of Operations recently bought kr80k worth of stock

Independent Director recently bought kr246k worth of stock

Now 22% overvalued after recent price rise

Iconovo AB (Publ) Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments

Consensus revenue estimates increase by 15%, EPS downgraded

New major risk - Shareholder dilution

Iconovo AB (publ) Receives Patent Protection for Icores in China

Iconovo AB (publ), Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: kr0.69 loss per share (vs kr1.35 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Iconovo AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 18.8 million.

Iconovo AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

New minor risk - Profitability

New major risk - Market cap size

Independent Chairman of the Board recently bought kr190k worth of stock

Third quarter 2023 earnings released: kr0.97 loss per share (vs kr1.14 loss in 3Q 2022)

Iconovo AB (publ) Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone

Iconovo AB (publ) Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations

Iconovo AB (Publ) Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027

New minor risk - Share price stability

New major risk - Financial position

Second quarter 2023 earnings released: kr1.36 loss per share (vs kr1.38 loss in 2Q 2022)

We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate

Price target decreased by 27% to kr63.00

Iconovo AB (publ) Strengthens its Customer Offering in the Novel Pharmaceuticals Business Segment

Iconovo AB (Publ) Announces Appoints Carl Lindgren as Chief Business Development Officer

Independent Director recently sold kr98k worth of stock

Independent Director recently sold kr171k worth of stock

Chief Executive Officer recently bought kr61k worth of stock

Independent Chairman of the Board recently bought kr100k worth of stock

Iconovo AB (publ) to Report Fiscal Year 2022 Results on Feb 08, 2023

Insufficient new directors

Iconovo Receives Approval of New European Patent for Its Single-Use Inhaler ICOone®

Iconovo AB (publ) Announces Executive Changes, Effective April 1, 2023

Iconovo's ICOone Inhaler Platform Receives New Patent Approval in the US

Iconovo Announces Appointment of Nomination Committee

Third quarter 2022 earnings released: kr1.14 loss per share (vs kr0.43 loss in 3Q 2021)

Iconovo AB (publ) Conducts a User Study to Assess the Handling of its ICOone Nasal Inhaler

Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation

Second quarter 2022 earnings released: kr1.38 loss per share (vs kr0.85 loss in 2Q 2021)

Iconovo AB (Publ) Announces First Patent Grant in Japan for It's ICOone

Chief Executive Officer recently bought kr69k worth of stock

Director recently bought kr258k worth of stock

Chief Executive Officer recently bought kr104k worth of stock

Price target increased to kr140

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Iconovo AB (publ) Announces Completion of Comparative Clinical Study of Icores Budesonide/Formoterol and Symbicort Turbuhaler

Chief Financial Officer recently bought kr53k worth of stock